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Abstract
Optimal treatment for patients with only local prostate cancer recurrence after external beam radiation therapy
(EBRT) failure remains unclear. Possible curative treatments are radical prostatectomy, cryosurgery, and brachytherapy. Several single institution series proved that high-dose-rate brachytherapy (HDRBT) and pulsed-dose-rate
brachytherapy (PDRBT) are reasonable options for this group of patients with acceptable levels of genitourinary and
gastrointestinal toxicity. A standard dose prescription and scheme have not been established yet, and the literature
presents a wide range of fractionation protocols. Furthermore, hyperthermia has shown the potential to enhance the
efficacy of re-irradiation.
Consequently, a prospective trial is urgently needed to attain clear structured prospective data regarding the efficacy of salvage brachytherapy with adjuvant hyperthermia for locally recurrent prostate cancer. The purpose of this
report is to introduce a new prospective phase II trial that would meet this need. The primary aim of this prospective
phase II study combining Iridium-192 brachytherapy with interstitial hyperthermia (IHT) is to analyze toxicity of the
combined treatment; a secondary aim is to define the efficacy (bNED, DFS, OS) of salvage brachytherapy. The dose
prescribed to PTV will be 30 Gy in 3 fractions for HDRBT, and 60 Gy in 2 fractions for PDRBT. During IHT, the prostate will be heated to the range of 40-47˚C for 60 minutes prior to brachytherapy dose delivery. The protocol plans for
treatment of 77 patients.
J Contemp Brachytherapy 2015; 7, 3: 254-258
DOI: 10.5114/jcb.2015.51871
Key words: clinical trial, high-dose-rate brachytherapy, hyperthermia, prostate cancer, pulsed-dose-rate brachytherapy.

Purpose
Approximately 10% of low-risk group patients and
up to 60% of high-risk group patients will experience biochemical recurrence (BF) [1-3]. Generally accepted and
most commonly applied definition of biochemical failure
after definitive RT is the Phoenix definition (PSA increase
of > 2 ng/ml above the nadir reached after RT) [4]. Metastatic or both metastatic and local disease are found in
about 50% of patients with biochemical progression who
have undergone previous radiotherapy. Local recurrence
only is found in 25% of patients with biochemical pro-

gression. The majority of local recurrences occur at the
site of dominant primary tumour [5].
There is no consensus with respect to optimal treatment in previously irradiated patients with sole local recurrence of prostate adenocarcinoma. There are only two
potentially curative treatment modalities for previously
irradiated recurrent prostate cancer: salvage surgery or
salvage brachytherapy; these have very similar efficacy
but different toxicities [6]. Salvage prostatectomy series
have demonstrated durable long term control. However,
aggressive salvage treatment options should be offered
with great care, because reported failure rates as well as
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toxicity rates can be significant, especially in inexperienced hands, regardless of salvage technique [7]. Other
treatment possibilities such as cryotherapy or high-intensity focused ultrasound (HIFU) are useful only for
carefully selected patients. In addition, HIFU is currently
not recommended as an alternative to accepted curative
treatment approaches for localized prostate cancer [8].
Androgen deprivation should be considered a palliative treatment. It is also not well tolerated by most
patients and has many side effects, e.g. insulin resistance and diabetes, bone loss, fatigue, sexual dysfunction
(erectile impotence, loss of libido), symptomatic gynecomastia, hot flushes, anaemia, and cardiovascular events.
Before deciding to perform local salvage therapy, metastases to regional lymph nodes and distant metastases
should be ruled out. It is also crucial to identify patients
that are most likely to have only local disease. Factors that
are associated with better biochemical control included
post-treatment PSA nadir of < 0.5 ng/ml, presalvage
PSA < 10, Gleason score < 8, PSADT (PSA doubling time)
> 6 months, disease free interval > 24 months, and low
risk initial tumor [6].
To date, there remains no consensus on standard
dose and fractionation scheme for salvage prostate HDR
brachytherapy. Previously published series of cases, as
well as ABS guidelines contain a wide range of prescribed
doses and various fractionation schemes [9].
Prostate brachytherapy allows the administration of
a high radiation dose in a small volume of tissue. Both
temporary implants (Ir-192) and permanent implants
(I-125, Pd-103) have been used for treatment of prostate
cancer recurrence after EBRT. There are few available
publications on HDRBT or PDRBT; most of them are retrospective studies that apply to small groups of patients
[10-16]. The results and toxicity are summarized in the
Table 1.
Preclinical studies have clearly demonstrated that
hyperthermia has the potential to enhance radiation re-

sponse by a factor of 1.4-2.0 [17]. In patients with radioresistant prostate cancer, the addition of hyperthermia
could potentially break down radiation resistance and
increase the chance of cure.
Consequently, a prospective trial is urgently needed
to attain clear structured prospective data regarding the
efficacy of salvage brachytherapy with adjuvant hyperthermia for locally recurrent prostate cancer. The purpose
of this report is to introduce a new prospective phase 2
trial that will evaluate the safety and effectiveness of temporary brachytherapy in combination with interstitial hyperthermia as a treatment for local recurrence of prostate
cancer after EBRT. The study will examine the side effects
of combined treatment, as well as its ability to cure the
cancer. A protocol of this clinical trial was designed by
the radiation oncologists from Krakow (Poland) and Erlangen (Germany) as an international multicenter study.

Material and methods
Study design
This is a prospective, multicenter non-randomized
phase II study. Patients are recruited during the radiation
therapy consultation in participating centers.

Eligibility criteria
Men with biopsy-confirmed locally recurrent prostate
adenocarcinoma in stage T1b-T3b N0/pN0 M0 are eligible for the study. Biopsy should be performed less than
6 months before registration and more than 24 months after initial EBRT. As evaluated with a TRUS volume study
performed 0-4 weeks before registration, each patient
should meet the eligibility criteria for prostate brachytherapy as follows: prostate/tumor volume < 60 ml,
the distance between rear prostate edge and rectal mucosa > 5 mm, interference of pubic arch ruled out, and, if
local stage T3b, it must be possible to cover the entire can-

Table 1. Toxicity and outcomes of salvage brachytherapy for prostate cancer recurrence after external beam
irradiation
Study, year

Salvage therapy

n

Median follow-up
(months)

Grade 3/4 toxicity

Outcome

Łyczek et al. [10]

HDR
30 Gy/3 fx/3 impl

115

No information

12.2% GU
0.9% GI

46% bPFS in patients with PSA < 6
18% bPFS in patients with PSA > 6

Scala et al. [11]

HDR
36 Gy/6 fx/2 impl

10

18.5

70% grade 2
or greater

70% dfs

Jo et al. [12]

HDR
22 Gy/2 fx/1 impl

11

29

0%

63% bNED

Morikawa et al. [13]

HDR
32 Gy/4 fx/1 impl

29

22

0%

79% bDFS

Chen et al. [14]

HDR
36 Gy/6 fx/2 impl

52

59.6

2%

51% 5y bDFS

Lahmer et al. [15]

PDR
60 Gy/2 impl

18

21

0-17%

57% PSA-rfsp

Kukiełka et al. [16]

HDR + IHT
30 Gy/3 fx/3 impl

25

13

0%

74% 2y bDFS

PSA-rfsp – PSA-recurrence free survival probability, bDFS – biochemical disease-free survival, bPFS – biochemical progression-free survival, bNED – biochemical no
evidence of disease, HDR – high-dose-rate brachytherapy, PDR – pulsed-dose-rate brachytherapy, IHT – interstitial hyperthermia; impl – implantation
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cer infiltration by the prescribed minimum brachytherapy dose.
The exclusion criteria are: TURP/prostatic salvage
cryosurgery/HIFU performed more than 6 months before registration, previous prostatectomy, androgen
deprivation therapy within 3 months prior to registration, performance status ECOG > 2, International Prostate Symptoms Score (IPSS) > 20, PSA doubling time
< 6 months, baseline gastrointestinal (GI) or genitourinary (GU) toxicity grade ≥ 2 as defined in Common Terminology Criteria for Adverse Events (CTCAE) version
4.0 [18]. Written study-specific informed consent will be
obtained from all the patients before study registration.

Primary endpoint
To estimate the rate of late Grade ≥ 3 gastrointestinal
(GI) and genitourinary (GU) toxicities related to salvage
treatment for locally recurrent prostate cancer after previous external beam radiation therapy. Treatment-related
toxicity will be evaluated according to the Common Toxicity Criteria for Adverse Events version 4.03 (CTCAE).

Secondary endpoints
1. To estimate the rate of acute treatment-related GI/
GU adverse events. 2. To determine time to biochemical
failure (Phoenix definition [4])/ biochemical disease-free
survival (bDFS), overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and clinical
patterns of tumor recurrence (time to local tumor progression or distant failure), as well as pre-treatment prognostic and/or predictive factors.

Sample size considerations
The sample size is calculated with type I error of 0.025,
type II error of 0.2 (power of 80%), and a one-sided hypothesis (only excess of cases is of interest). Conservatively assuming a ‘normal’ rate of 10% grade 3 or higher late
toxicity, 70 patients are needed to exclude that the rate is
actually ≥ 20%, i.e., unacceptable, with the necessary precision. This sample size calculation is based directly on
the binomial distribution. Adjusting the number of cases
for ineligible or unanalyzable cases by 10%, a minimum
sample size of 77 patients is required for this study.

Brachytherapy
Implantation procedure
The implant procedure will be performed according to
the standard technique. A Foley catheter will be inserted
to visualize the urethra at the beginning of the procedure.
The patient will be positioned in the lithotomy position,
centered on the table. The ultrasound probe will be inserted into the rectum and adjusted to provide a satisfactory image without distorting the contour of the prostate.
Row #1 on the template matrix is positioned within the
prostate on the axial image, on which the prostate is most
posteriorly situated and is anterior to the rectum at all
levels. Afterloading catheters may be placed with TRUS
or MR guidance. The implant catheters must be non-me-

tallic (for hyperthermia use). The implant procedure may
be done under spinal or general anesthesia. During the
implant, attention should be given to keep the catheters
in the prostate without perforating the urethra. Posterior
rows of catheters may be advanced into the seminal vesicles under TRUS guidance.

Treatment planning transrectal ultrasonography
Treatment planning will be based on a real time TRUS
volume study of the prostate. It is acceptable also to use
MRI based treatment planning. The ultrasound probe
will be advanced until the base of the prostate is visualized, and this level will be designated the base plane.
Contiguous serial axial images of the prostate at ≤ 3 mm
increments beginning 5-10 mm cranial to the base plane
(including all the catheters tips) will be obtained and
will extend > 5 mm inferior (caudal) to the apex of the
prostate. The CTV will be outlined on each axial image
where it is present. The use of dwell time in dwell positions located outside of the PTV is discouraged to minimize normal tissue irradiation. A dwell time optimization program based on geometric or inverse and manual
planning algorithm may be used.
The target volume definitions are largely based on
those provided in ICRU Report 58: Dose and Volume
Specification for reporting interstitial therapy [19]. The
Clinical Target Volume (CTV) for stages T1-T2 includes
the TRUS-defined prostate volume. For T3 stages, the
CTV includes the whole prostate gland and extracapsular/seminal vesicle invasion. The Planning Target Volume (PTV) is the same as CTV. Additional 1-3 mm margins may be added in case of uncertainty of extracapsular
infiltration.

Dose specifications, dose fractionation
In this trial, the dose prescribed to the PTV will be 30 Gy
in three 10 Gy fractions spaced 21 days apart for HDRBT
(the most common fractionation scheme in Poland) and
60 Gy in 2 fractions spaced 28 days apart for PDRBT
(scheme from Erlangen). In both protocols, the brachytherapy will follow interstitial hyperthermia treatment.
To compare the expected biological effect of different
fractionation schedules, the calculations were made using
the linear-quadratic model [20] for the total biologically
equivalent doses in 2-Gy fractions EQD2 both for HDRBT
and PDRBT with multiple fractions (see Table 2).

Dose-volume histogram (DVH) parameters,
reporting
The following dose parameters for CTV must be reported: D90, DMIN, V100, V150, V200. The essential conditions are: D90 > 100%, V100 > 90-95%. The required DVH
parameters for the rectum and bladder (if contoured) are
D0,1cc, D1cc, D2cc. The dose constraint for the rectum is D2cc
< 50 Gy (EQD2 for α/β = 3) (for HDRBT D2cc < 7.75 Gy
per fraction), and for the bladder is D2cc < 60 Gy (EQD2
for α/β = 3) (for HDRBT D2cc < 8.6 Gy per fraction). The
urethra DVH parameters are D0,1cc, D10, and D30. The dose
constraint is D0,1cc < 120% of the prescribed dose.
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Table 2. Comparison of equivalent doses in 2-Gy fractions (EQD2) of the proposed treatment schemes
α/β = 1 Gy

α/β = 3 Gy

α/β = 10 Gy

EQD2Gy (PDR: 2 × 30 Gy = 2 × (50 × 0.6 Gy)); T1/2 = 1.9 h

79.08

71.45

64.77

EQD2Gy (HDR: 30 Gy = 3 × 10 Gy)

110.00

78.00

50.00

α/β – alpha/beta ratio, T1/2 – half-time to repair, HDR – high-dose-rate brachytherapy, PDR – pulsed-dose-rate brachytherapy

Hyperthermia
Interstitial hyperthermia (IHT) treatment is scheduled
before every brachytherapy fraction and it should end no
more than one hour before the start of irradiation. Hyperthermia will be carried out in accordance with the QA
guidelines published by the RTOG for interstitial hyperthermia [21]. Catheters implanted to the prostate during
the implantation procedure will be used to place microwave antennas and temperature probes. At least eight,
but as many catheters as possible should be placed in the
prostate for microwave antennas and thermal sensors.
The distance between antennas should be at least 5 mm
and at most 15 mm.
Thermometry probes should be positioned in the
rectum and urethra near the prostate implant catheters,
inside the urinary catheter, and in the prostate tissue (at
least 2 probes) for continuous thermometry and thermal
mapping of tumor-related temperatures. The objective of
treatment is to achieve a tumor/prostate temperature of
40-47°C. Therapeutic time starts when 40°C is achieved
in at least one of the prostatic thermometry sensors or
30 minutes after enabling power. Planned treatment time
is 60 minutes, and a maximum duration of 90 minutes of
applied power is permitted. Failure to achieve 40°C in at
least one prostate location for 30 minutes in at least two
sessions will make the case not evaluable for response and
toxicity. Hyperthermia withdrawal or shortening therapeutic time to 30 minutes is permitted in case of: 1. early
weakening of spinal anaesthesia; 2. excessive patient mobility (risk of catheter displacement) or 3. patient request.

Treatment schedules
For HDR brachytherapy:
Day 1: IHT for 60 minutes followed by HDR within 60 min;
Day 22: IHT for 60 minutes followed by HDR within 60 min;
Day 43: IHT for 60 minutes followed by HDR within 60 min.
For PDR brachytherapy:
Day 1-3: IHT 60 minutes followed by PDR within 60 min;
Day 29-31: IHT 60 minutes followed by PDR within 60 min.

Study duration
The protocol was activated in February 2014 after receiving the vote of Ethics Committee of Chamber of Physicians in Krakow. The duration of patient recruiting is
scheduled for approximately 3-4 years.

Conclusions
The standard dose prescription and schedule are not
established yet for salvage brachytherapy re-irradiation of
locally recurrent prostate cancer. The literature presents

a wide range of treatment protocols. Consequently, a prospective trial is urgently needed to attain clear structured
prospective data. The purpose of this report is to introduce
a new prospective phase 2 trial combining Iridium-192
brachytherapy with interstitial hyperthermia (IHT). The
primary aim of this trial is to analyze toxicity of the combined treatment, and the secondary aim is to define the
efficacy (bNED, DFS, OS) of salvage brachytherapy and
heat. The radiation dose prescribed to the PTV is 30 Gy in
3 fractions for HDR-brachytherapy and 60 Gy in 2 fractions
for PDR-brachytherapy. The thermal dose prescribed to
the PTV is a range of 40-47°C for 60 min. The protocol anticipates treatment of 77 patients and the trial is currently
open for participation by additional study centers.
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